Crucell continues shift to in-house product development

- Last updated on GMT

Related tags: Vice president of the united states, Crucell

Dutch biotechnology company Crucell has put in place another
element in its strategy to develop in-house drug products functions
with the appointment of a new vice president of development.

Dutch biotechnology company Crucell has put in place another element in its strategy to develop in-house drug products functions with the appointment of a new vice president of development.

Jean-Yves Guichoux joins the company from Afforce Healthcare and was previously head of clinical research at Yamanouchi Europe.

In June, Crucell started developing a West Nile virus vaccine in what marked a significant departure for the company. This was one of the first vaccines that the company opted to develop and market under its own banner, rather than relying on royalties from partners relating to the use of its PER.C6 cell line for vaccine production.

Indeed, this reflects the prevailing sentiment that technology platform companies should make the transition to in-house product development in order to ensure their long-term success.

Jaap Goudsmit, Crucell's chief scientific officer, said that, now, "product development is Crucell's focus."​ He noted that Dr Guichoux is responsible for the Dutch company's product development programmes and will oversee each project from preclinical development, through to clinical trials and subsequent product registration.

Crucell is holding an analyst meeting and webcast on Friday, 21 November. During the meeting, the firm's senior scientific staff and executive management team will present a comprehensive update on the company's product development plans and progress, including the most recent data available on its key vaccine programs.

Related topics: Ingredients

Related news

Show more

Follow us

Products

View more

Webinars